ArticleACS omega2026
Transplacental Transfer of Telbivudine in Hepatitis B Virus-Infected Pregnant Women Treated with Telbivudine during the Third Trimester.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telbivudine is an FDA-approved pregnancy category B drug for the treatment of chronic hepatitis B virus (HBV) infection. It has been used in HBV-carrier women with high viremia to prevent mother-to-child transmission of HBV. However, placental transfer of telbivudine from mother to fetus has not been studied. Using a sensitive ultraperformance liquid chromatography-tandem mass spectrometry method, we measured the concentration of telbivudine in maternal blood collected at delivery from 29 pregnant women, who took telbivudine (daily 600 mg) from gestation week 28-32 to week 4 postpartum, with a median interval of 8.0 (range 6.5-15.5) h between the final dose and sampling, and in cord blood collected from umbilical arteries of 29 placentas immediately after birth. The concentrations of telbivudine in maternal blood varied between 77.6 and 2920 ng/mL, with a median concentration of 379.0 ng/mL, while the concentrations in cord blood ranged from 107.0 to 2250 ng/mL, with a median concentration of 426.0 ng/mL. The concentration between the maternal and fetal circulations had no statistically significant difference (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.